Related Experiment Video
Updated: Jun 26, 2026
Mouse Model of Acute to Chronic Kidney Disease Transition Induced by Renal Ischemia/Reperfusion Injury
Published on: February 10, 2026
Association between Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients with Chronic
Jing Zhou1,2, Junjuan Li2, Yan Xu3
1Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
Insights
Percutaneous coronary intervention (PCI) after acute myocardial infarction (AMI) in patients with chronic kidney disease (CKD) reduced mortality within 5 years. However, PCI did not significantly impact new heart failure or CKD progression.
Area of Science:
- Cardiology
- Nephrology
- Clinical Research
Background:
- Patients with chronic kidney disease (CKD) face elevated risks following acute myocardial infarction (AMI).
- Long-term outcomes after percutaneous coronary intervention (PCI) in CKD patients with AMI require further investigation.
Purpose of the Study:
- To evaluate the long-term impact of PCI on mortality, heart failure, and CKD progression in AMI patients with CKD.
Main Methods:
- A prospective cohort study within the Kailuan Study (2006-2020) included CKD patients with AMI.
- Participants were matched (1:2) by age and sex into PCI (n=452) and non-PCI (n=745) groups.
- Outcomes assessed included all-cause mortality, new-onset heart failure, and CKD progression using Cox models.
Main Results:
- PCI was linked to reduced all-cause mortality, particularly within the first 5 years (HR 0.34).
- This mortality benefit attenuated after 5 years (HR 0.73).
- No significant associations were found between PCI and new-onset heart failure (HR 1.06) or CKD progression (HR 1.11).
Conclusions:
- PCI in CKD patients with AMI is associated with decreased all-cause mortality within the initial 5 years post-intervention.
- PCI demonstrated no significant effect on the incidence of new heart failure or the progression of CKD.
Introduction:
Patients with chronic kidney disease (CKD) are at a high risk of adverse outcomes after acute myocardial infarction (AMI); however, evidence on long-term outcomes after percutaneous coronary intervention (PCI) in this population remains limited.
Methods:
This prospective cohort study, nested within the Kailuan Study, included patients with CKD who experienced AMI between 2006 and 2020. Participants were classified into PCI and non-PCI groups based on documented PCI receipt and were matched 1:2 on age and sex (452 PCI; 745 non-PCI). Follow-up began at the time of AMI diagnosis or PCI and continued until December 31, 2023. The primary outcome was all-cause mortality, with secondary outcomes being new-onset heart failure and CKD progression. Time-segmented Cox models were used for all-cause mortality, and standard Cox models were used for secondary outcomes.
Results:
During follow-up, PCI receipt was associated with a lower risk of all-cause mortality compared with no PCI. The association was stronger during the first 5 years of follow-up (hazard ratio [HR], 0.34; 95% confidence interval [CI], 0.24-0.47) and was attenuated thereafter (HR, 0.73; 95% CI, 0.51-1.04). No significant associations were observed between PCI receipt and either new-onset heart failure (HR, 1.06; 95% CI, 0.72-1.57) or CKD progression (HR, 1.11; 95% CI, 0.72-1.71).
Conclusion:
In patients with CKD and AMI, PCI was associated with lower all-cause mortality during the first 5 years of follow-up, with no significant differences in new-onset heart failure or CKD progression.
Related Concept Videos
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:28Chronic Kidney Disease III: Interprofessional Care
01:25Chronic Kidney Disease I: Introduction
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:29Acute Kidney Injury III: Clinical Manifestations
01:20Acute Kidney Injury V: Interprofessional Care